NCT03464942: Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

NCT03464942
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Active brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03464942

Comments are closed.

Up ↑